Skip to main content

Adc Therapeutics Sa(ADCT-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume

Latest News

ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
Business Wire - Wed Sep 21, 6:00PM CDT
Business Wire
Wed Sep 21, 6:00PM CDT
ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA ® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO...
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Business Wire - Fri Sep 16, 6:15AM CDT
Business Wire
Fri Sep 16, 6:15AM CDT
ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing...
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
Business Wire - Wed Sep 14, 10:17AM CDT
Business Wire
Wed Sep 14, 10:17AM CDT
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or “the Company”) (NYSE: ADCT ) for violations of the securities laws.
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
Business Wire - Tue Sep 13, 7:19PM CDT
Business Wire
Tue Sep 13, 7:19PM CDT
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or “the Company”) (NYSE: ADCT ) for violations of the securities laws.
ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference
Business Wire - Tue Sep 6, 6:15AM CDT
Business Wire
Tue Sep 6, 6:15AM CDT
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20 th Annual Global Healthcare Conference on Tuesday, September 13 th at 11:45 a.m. ET.
ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes
Business Wire - Mon Aug 15, 3:30PM CDT
Business Wire
Mon Aug 15, 3:30PM CDT
ADC Therapeutics SA (NYSE: ADCT) today announced that it has completed a series of strategic transactions in which it:
ADC Therapeutics SA (ADCT) Q2 2022 Earnings Call Transcript
Motley Fool - Tue Aug 9, 11:01PM CDT
Motley Fool
Tue Aug 9, 11:01PM CDT
ADCT earnings call for the period ending June 30, 2022.
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
Business Wire - Tue Aug 9, 6:00AM CDT
Business Wire
Tue Aug 9, 6:00AM CDT
ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2022 and provided business updates.
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
Business Wire - Tue Aug 2, 6:15AM CDT
Business Wire
Tue Aug 2, 6:15AM CDT
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report financial results for the second quarter 2022 and provide business updates.
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
Business Wire - Wed Jul 27, 6:15AM CDT
Business Wire
Wed Jul 27, 6:15AM CDT
ADC Therapeutics SA (NYSE: ADCT) today announced the first patient has been dosed in the Phase 1b clinical trial evaluating ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and in combination with gemcitabine in patients with...